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Introduction
In 1992 a new syndrome consisting of syncopal episodes and/or sudden death in patients with a 
structurally normal heart and a characteristic electrocardiogram (ECG) with a pattern of right 
bundle branch block with an ST segment elevation in leads V1 to V3 was described 1 In 1998 
the poor prognosis of patients with the syndrome not receiving an implantable defibrillator was 
reported 2,3 In 1998 the genetic nature of the disease and its assotiation to a mutation in the 
cardiac sodium channel gene was described 4 . Because the diagnosis is easily made by means of 
the ECG, an increasing number of patients with the ECG pattern are being identified worldwide. 
In this article we will review our present knowledge concerning patients with the classical ECG 
pattern of the disease. 
            In the Brugada syndrome, the diagnosis is based on the history of aborted sudden death 
with the typical electrocardiographic pattern of ST segment elevation in leads V1-V3, with or 
without right bundle branch block 1 ( Fig. 1). In some cases, however, the diagnosis is different 
because some individuals present with an abnormal electrocardiogram but are completely 
asymptomatic or there is a history of sudden death in the family and the electrocardiographic 
criteria are observed.
Incidence of an abnormal ECG in the general population
A prospective study of an adult Japanese population (22,027 subjects) showed an incidence of 
0.05% of ECG’s compatible with the syndrome (12 subjects)5. A second study of adults in Awa 
(Japan) showed an incidence of 0.6 % (66 cases out of 10,420) 6. However, a third study in 
children from Japan showed an incidence of ECG's compatible with the syndrome of only 
0.0006% (1 case in 163,110)7. These results suggest that the syndrome manifests primarily 
during adulthood, which is in concordance with the mean age of sudden death victims (35 to 40 
years).
 The presence of concealed and intermittent forms, however, makes the diagnosis difficult in 
some  patients.  The  ECG  can  be  modulated   by  changes  in  autonomic  balance  and  the 
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administration of antiarrhythmic drugs8. Beta-adrenergic stimulation normalises the ECG, while 
IV ajmaline, flecainide or procainamide accentuate the ST segment elevation and are capable of 
unmasking concealed and intermittent forms of the disease. These data are very important when 
we deal with family members of a patient with the syndrome. We know that a normal ECG in 
the resting state is not sufficient to exclude that a family member is affected with the syndrome. 
Some family members only manifest the typical ECG pattern after ajmaline or flecainide 
administration.
 
 Fig. 1. Typical ECG of the syndrome. Please note the pattern resembling a right bundle branch 
block in lead V1 and the ST segment elevation in leads V1 to V3. Paper speed 25 mm/s. 
Recent data suggest that loss of the action potential dome in right ventricular epicardium but not 
endocardium underlies the ST segment elevation seen in the Brugada syndrome  9,10. Also, 
electrical heterogeneity within right ventricular epicardium leads to the development of closely 
coupled extrasystoles via a phase 2 reentrant mechanism, which then precipitate ventricular 
tachycardia-ventricular   fibrillation.   Right   ventricular   epicardium   is   preferentially   affected 
because of the predominance of transient outward current in this tissue.  
Clinical manifestations
The complete syndrome is characterised by episodes of rapid polymorphic VT in patients with 
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an ECG pattern of right bundle branch block and ST segment elevation in leads V1 to V3. The 
manifestations of the syndrome are caused by episodes of polymorphic VT/VF. When the 
episodes terminate spontaneously the patient develops syncopal attacks. When the episodes are 
sustained, cardiac arrest and eventually sudden death occur.
There exist asymptomatic individuals in whom the atypical ECG is detected during routine 
examination. This ECG cannot be distinguished from that of symptomatic patients. In other 
patients, the characteristic ECG is recorded during screening after the sudden death of a family 
member with the disease.
On the other hand, there is the group of symptomatic patients who have been diagnosed as 
suffering syncopal episodes of unknown cause, or vaso-vagal origin, or have a diagnosis of 
idiopathic ventricular fibrillation. Some of these patients are diagnosed at follow-up, when the 
ECG changes spontaneously from normal to the typical pattern of the syndrome. This is also the 
case for those individuals in whom the disease is unmasked by the administration of an 
antiarrhythmic drug given for other arrhythmias, for instance atrial fibrillation.
Diagnosis.
The diagnosis of the syndrome is easily obtained by electrocardiography as long as the patient 
presents the typical ECG pattern and there is a history of aborted sudden death or syncopes 
caused by a polymorphic VT. The ST segment elevation in V1 to V3 with the right bundle 
branch block pattern is characteristic. The ST changes are different from the ones observed in 
acute septal ischemia, pericarditis, ventricular aneurysm and in some normal variants like early 
repolarization. There are though, ECG's which are not as characteristic, and they are only 
recognised by a physician who is thinking of the syndrome. There are also many patients with a 
normal ECG in whom the syndrome can only be recognised a posteriori when the typical pattern 
appears in a follow-up ECG or after the administration of ajmaline, procainamide or flecainide.
It is possible that the electrocardiographic patterns are different depending on the genetic 
abnormality. This is the case in other genetic diseases like the long QT syndrome  11. The 
mutations that have been discovered give proof of this fact in Brugada syndrome: their ECG's 
are similar, but not identical. Even though the affected gene is the same, the exact mutation is 
different. It will be necessary to identify more mutations and make close genotype-phenotype 
correlation to establish the links. However, we cannot forget the great variability of the ECG in 
this syndrome, something which will certainly not facilitate analysis.
Additional diagnostic problems are caused by the changes in the ECG induced by the 
autonomous system and by antiarrhythmic drugs. The study by Myazaki et al 8 was the first one 
to show the variability of the ECG pattern in the syndrome. Despite the fact that we described 
the syndrome as a persistent ECG pattern, we soon recognised that it is variable over time, 
depending on the autonomic interaction and the administration of antiarrhythmic drugs. 
Adrenergic stimulation decreases the ST segment elevation while vagal stimulation worsens it. 
The administration of class Ia, Ic and III drugs increase the ST segment elevation. Patients with 
syncope of unknown cause must be challenged with antiarrhythmic drugs in order to exclude the 
possibility of this syndrome as a cause of ventricular arrhythmias and syncope.
Genetic characterisation.
In the Brugada syndrome, as in the long QT syndrome, the best candidate genes are those that 
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are responsible for the formation of the cardiac action potential, namely the genes that encode for 
the   cardiac   ionic   channels.   In   animal   studies,   blockade   of   the   calcium-independent   4-
aminopyridine-sensitive transient  outward  potassium current (Ito)  results  in surface  ECG 
findings of elevated, downsloping ST-segments due to greater prolongation in the epicardial 
action potential compared to the endocardium (which lacks a plateau phase). Loss of the action 
potential plateau (or dome) in the epicardium but not endocardium would be expected to cause 
ST-segment elevation. Because loss of the dome is caused by an outward shift in the balance of 
currents active at the end of phase 1 of the action potential (principally Ito and ICa), autonomic 
neurotransmitters like acetylcholine facilitate loss of the action potential dome by suppressing 
calcium current and augmenting potassium current.  b-adrenergic agonists (i.e. isoproterenol, 
dobutamine) restore the dome by augmenting ICa.  Sodium channel blockers also facilitate loss 
of the canine right ventricular action potential dome as a result of a negative shift in the voltage 
at which phase 1 begins.  Hence, Ito, ICa, and INa would be good candidate genes to study. Since 
INa (SCN5A) has been shown to cause VT/VF in humans (in the long QT syndrome) this gene 
certainly is worthy of study.
Recently, we reported the findings on six families and several sporadic cases of Brugada 
syndrome 4.  The families were initially studied by linkage analysis using markers to the known 
ARVD loci and linkage was excluded.  More recently, seven other families have also excluded 
linkage to these loci, thus suggesting that the families recruited with the Brugada syndrome to 
date may indeed by an entity distinct from ARVD. Candidate gene screening using the mutation 
analysis approach of single strand conformation polymorphism (SSCP) analysis and DNA 
sequencing was performed and SCN5A was chosen for study.  In three families, mutations in 
SCN5A were identified including: 1.- a missense mutation (C-to-T base substitution) causing a 
substitution of a highly conserved threonine by methionine at codon 1620 (T1620M) in the 
extracellular loop between transmembrane segments S3 and S4 of domain IV (DIVS3 - DIVS4), 
an area important for coupling of channel activation to fast inactivation; 2.- a two nucleotide 
insertion (AA) which disrupts the splice-donor sequence of intron 7 of SCN5A; and 3.- a single 
nucleotide deletion (A) at codon 1397 which results in an in-frame stop codon that eliminates 
DIIIS6, DIVS1 - DIVS6, and the carboxy-terminus of SCN5A. Not all the individuals had the 
typical electrocardiogram at baseline. The diagnosis for genetic purposes was based on the 
electrocardiographic changes after the administration of ajmaline iv. This test proved 100% 
sensitive and specific, as all the patients who developed the ST segment elevation had the 
mutation in the subsequent genetic analysis. Likewise, none of the individuals without the 
electrocardiographic abnormalities had the genetic abnormality.
Biophysical analysis of the mutants in Xenopus oocytes demonstrated a reduction in the number 
of functional sodium channels in both the splicing mutation and one-nucleotide deletion 
mutation, which  should  promote  development of  reentrant  arrhythmias.  In  the missense 
mutation, sodium channels inactivated more rapidly than normal. In this case, the presence of 
both normal and mutant channels in the same tissue would promote heterogeneity of the 
refractory period, a well-established mechanism of arrhythmogenesis.  Inhibition of the sodium 
channel INa  current causes heterogeneous loss of the action potential dome in the right 
ventricular epicardium, leading to a marked dispersion of depolarisation and refractoriness, an 
ideal substrate for development of reentrant arrhythmias.  Phase 2 reentry produced by the same 
substrate is believed to provide the premature beat necessary for initiation of the VT and VF 
responsible for symptoms in these patients.
Indian Pacing and Electrophysiology Journal (ISSN 0972-6292), 1(1): 6-11 (2001)Josep Brugada, Pedro Brugada, Ramon Brugada, “Brugada Syndrome:                          10 
The Syndrome of Right Bundle Branch Block, ST segment Elevation in V1 to V3 and Sudden 
Death”
Mutations in the SCN5A gene were previously shown to be the cause of LQT3, a form of 
Romano-Ward long QT syndrome. The differences in the clinical findings between LQT3 and 
Brugada syndrome occur due to the different biophysical results based on the position of the 
mutations within the gene. Unlike the Brugada syndrome, LQT3 occurs due to an augmentation 
of late INa carried by SCN5A channels.
Prognosis and treatment.
Symptomatic patients: Our recent data on 334 patients with the syndrome confirm the generally 
accepted view that symptomatic patients with this syndrome have an unacceptably high rate of 
arrhythmic events. Because no effective antiarrhythmic drug or other therapies are available, 
implantation of a cardioverter-defibrillator is mandatory in these patients. Better understanding 
of the genetic basis and electrophysiologic mechanisms of the disease may make other therapies 
possible in the future. Recurrent arrhythmic events were more frequent in patients with aborted 
sudden death as the presenting symptom as compared to patients with repetitive syncopal 
episodes. This could suggest a more severe disease in the former group with more frequent and 
longer-lasting arrhythmias. However, a word of caution is in order because the mean follow-up 
period of patients with aborted sudden death was significantly longer than the mean follow-up of 
patients with syncopal episodes. For both categories of symptomatic patients, the recurrence 
rates approximate a mean of 11% per mean follow-up year (8.8% per year in syncope patients 
and 13.7% per year in patients resuscitated from sudden cardiac death) and are unacceptably 
high. The gravity of the problem is amplified when one considers the mean age of the patients.
            Asymptomatic individuals: The major concern at present is with the group of individuals 
displaying an electrocardiogram compatible with the diagnosis of Brugada syndrome but who 
are asymptomatic. The initial diagnosis in these individuals was arrived at by different means: In 
some individuals a spontaneously abnormal electrocardiogram was recorded as part of a routine 
screening, for instance before surgery. In other individuals, the abnormal electrocardiogram was 
obtained because of a family history of sudden death. In some, the abnormal electrocardiogram 
appeared only during treatment with antiarrhythmic drugs given for the treatment of atrial 
fibrillation or other arrhythmias. Finally, in still others, the abnormal electrocardiogram was 
obtained   only   after   pharmacologic   challenge   performed   because   of   the   suspicion   or 
documentation of Brugada syndrome in the family. The most recent data allow important 
conclusions in terms of the management of these asymptomatic individuals.
First, it is confirmed that a spontaneously abnormal electrocardiogram is a marker of possible 
sudden arrhythmic death: 16 of 111 (14%) asymptomatic individuals with a spontaneously 
abnormal electrocardiogram developed an arrhythmic event during a mean follow-up period of 
only 27±29 months. The arrhythmic event occurred within one year of diagnosis in 7 individuals, 
within 2 years in another 3 patients, but after more than 4 years in the remaining 6 individuals. 
The longest time interval between diagnosis and first arrhythmic event was 10 years. These data 
demonstrate that a mean follow-up time of slightly more than 2 years underestimates the total 
number of events that can occur in this population.
Second, the data allowed recognition of groups of asymptomatic individuals with a good 
prognosis. The group of asymptomatic individuals in whom the abnormal electrocardiogram 
was recognized only after pharmacologic challenge  had no events during   follow-up. This 
observation has important implications for the management of individuals who are members of a 
family with Brugada syndrome. When the individual is asymptomatic and the electrocardiogram 
is normal, the unmasking of the abnormal electrocardiogram with a drug identifies a carrier of 
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the disease. However, because no events occurred in this group, it is not justified to recommend 
further investigations in terms of management.
Conclusions.
The syndrome of right bundle branch block, ST segment elevation from V1 to V3 and sudden 
death is a new entity. This disease is genetically determined and it is different from the long QT 
syndrome and right ventricular dysplasia. The incidence of sudden death in this syndrome is very 
high and, at present, sudden death can only be prevented by implanting a cardioverter-
defibrillator.
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